Spektrum der Augenheilkunde

, Volume 25, Issue 5, pp 319–330

Pharmakologische Therapie der Frühgeborenenretinopathie

Fortbildung
  • 39 Downloads

Zusammenfassung

Ein verbindlich festgelegtes Screening durch erfahrene Ophthalmologen ist nach wie vor die wichtigste Säule im Management der Frühgeborenenretinopathie (ROP). Den derzeitigen Goldstandard zur Therapie der proliferativen ROP stellt nach wie vor die panretinale Laserkoagulation dar, je nach Schwere ggf. in Kombination mit vitreoretinaler Chirurgie. Die ersten Fallserien zur "off-label" durchgeführten intravitrealen Anti-VEGF-Therapie sind ermutigend. Neben der intravitrealen Anti-VEGF-Therapie stellen auch Behandlungskonzepte wie die Supplementation von IGF-1 oder ω3-Fettsäuren interessante pharmakologische Ansätze zur Behandlung der ROP dar. Allerdings müssen auch diese systemischen Therapieansätze ihren Nutzen und ihre Sicherheit erst in größeren kontrollierten Studien unter Beweis stellen.

Schlüsselwörter

Frühgeborenenretinopathie Pharmakologische Therapie Anti-VEGF-Therapie ω3-Fettsäuren IGF-1 

Pharmacological treatment for retinopathy of prematurity

Summary

Mandatory screening performed by an experience ophthalmologist remains the most important pillar in the management of retinopathy of prematurity (ROP). The current gold standard for treatment of proliferative ROP is still panretinal laser photocoagulation, depending on severity, in combination with vitreoretinal surgery if necessary. The first case series of off-label intravitreal anti-VEGF treatment are encouraging. In addition to intravitreal anti-VEGF therapy, other treatment concepts such as supplementation with IGF-1 or omega-3 fatty acids also represent interesting pharmacological approaches to the management of ROP. However, larger controlled trials are required to validate the benefits and safety of these systemic treatment approaches.

Keywords

Retinopathy of prematurity Pharmacological treatment Anti-VEGF therapy Omega-3 fatty acids IGF-1 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur (Auswahl)

  1. Atchaneeyasakul LO, Trinavarat A (2010) Choroidal ruptures after adjuvant intravitreal injection of bevacizumab for aggressive posterior retinopathy of prematurity. J Perinatol 30:497–499PubMedCrossRefGoogle Scholar
  2. Chung EJ, Kim JH, Ahn HS, Koh HJ (2007) Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 245:1727–1730PubMedCrossRefGoogle Scholar
  3. Hellstrom A, Engstrom E, Hard AL et al (2003) Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics 112:1016–1020PubMedCrossRefGoogle Scholar
  4. Hoang QV, Kiernan DF, Chau FY et al (2010) Fluorescein angiography of recurrent retinopathy of prematurity after initial intravitreous bevacizumab treatment. Arch Ophthalmol 128:1080–1081PubMedCrossRefGoogle Scholar
  5. Honda S, Hirabayashi H, Tsukahara Y, Negi A (2008) Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 246:1061–1063PubMedCrossRefGoogle Scholar
  6. Jandeck C (2009) New therapeutic approaches in the treatment of retinopathy of prematurity. Klin Monatsbl Augenheilkd 226:914–920PubMedCrossRefGoogle Scholar
  7. Kusaka S, Shima C, Wada K et al (2008) Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol 92:1450–1455PubMedCrossRefGoogle Scholar
  8. Kychenthal A, Dorta P (2010) Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity. Retina 30:S32–S36PubMedCrossRefGoogle Scholar
  9. Lalwani GA, Berrocal AM, Murray TG et al (2008) Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 28:S13–S18PubMedCrossRefGoogle Scholar
  10. Lee JY, Chae JB, Yang SJ et al (2010) Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Graefes Arch Clin Exp Ophthalmol 248:1257–1262PubMedCrossRefGoogle Scholar
  11. Lorenz B (2008) Current ophthalmic aspects of acute retinopathy of prematurity. Ophthalmologe 105:1092–1100PubMedCrossRefGoogle Scholar
  12. Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364:603–615PubMedCrossRefGoogle Scholar
  13. Mintz-Hittner HA, Kuffel RR Jr (2008) Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 28:831–838PubMedCrossRefGoogle Scholar
  14. Nazari H, Modarres M, Parvaresh MM, Falavarjani KG (2010) Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage. Graefes Arch Clin Exp Ophthalmol 248:1713–1718PubMedCrossRefGoogle Scholar
  15. Nonobe NI, Kachi S, Kondo M et al (2009) Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab. Retina 29:579–585PubMedCrossRefGoogle Scholar
  16. Pieh C, Agostini H, Buschbeck C et al (2008) VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity. Br J Ophthalmol 92:689–693PubMedCrossRefGoogle Scholar
  17. Pieh C, Kruger M, Lagreze WA et al (2010) Plasma sE-selectin in premature infants: a possible surrogate marker of retinopathy of prematurity. Invest Ophthalmol Vis Sci 51:3709–3713PubMedCrossRefGoogle Scholar
  18. Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML et al (2008) Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 28:S19–S25PubMedCrossRefGoogle Scholar
  19. Sapieha P, Stahl A, Chen J et al (2011) 5-lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of {omega}-3 polyunsaturated fatty acids. Sci Transl Med 3:69ra12PubMedCrossRefGoogle Scholar
  20. Sato T, Kusaka S, Shimojo H, Fujikado T (2009) Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology 116:1599–1603PubMedCrossRefGoogle Scholar
  21. Sato T, Shima C, Kusaka S (2011) Vitreous levels of angiopoietin-1 and angiopoietin-2 in eyes with retinopathy of prematurity. Am J Ophthalmol 151:353–357, e35PubMedCrossRefGoogle Scholar
  22. Shah PK, Morris RJ, Narendran V, Kalpana N (2011) Visual acuity and electroretinography findings 3 (1/2) years after the first intravitreal injection of bevacizumab (Avastin) in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol 59:73–74PubMedCrossRefGoogle Scholar
  23. Smith LE (2008) Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci 49:5177–5182PubMedCrossRefGoogle Scholar
  24. Smith LE, Shen W, Perruzzi C et al (1999) Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 5:1390–1395PubMedCrossRefGoogle Scholar
  25. Smith LE, Wesolowski E, McLellan A et al (1994) Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35:101–111PubMedGoogle Scholar
  26. Stahl A, Connor KM, Sapieha P et al (2010) The mouse retina as an angiogenesis model. Invest Ophthalmol Vis Sci 51:2813–2826PubMedCrossRefGoogle Scholar
  27. Stahl A, Sapieha P, Connor KM et al (2010) Short communication: PPAR gamma mediates a direct antiangiogenic effect of omega 3-PUFAs in proliferative retinopathy. Circ Res 107:495–500PubMedCrossRefGoogle Scholar
  28. Travassos A, Teixeira S, Ferreira P et al (2007) Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging 38:233–237PubMedGoogle Scholar
  29. Wu WC, Yeh PT, Chen SN et al (2011) Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan. Ophthalmology 118:176–183PubMedCrossRefGoogle Scholar
  30. Zepeda-Romero LC, Liera-Garcia JA, Gutierrez-Padilla JA et al (2010) Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity. Eye (Lond) 24:931–933CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • A. Stahl
    • 1
  • H. Agostini
    • 1
  • C. Jandeck
    • 2
  • W. Lagrèze
    • 1
  1. 1.Universitätsaugenklinik FreiburgFreiburg
  2. 2.Artemis KlinikenFrankfurt am MainGermany

Personalised recommendations